sur Mainz BioMed N.V.
Mainz Biomed Collaborates with Thermo Fisher for Cancer Screening Development
Mainz Biomed N.V. has announced a collaboration with Thermo Fisher Scientific to develop next-generation colorectal cancer screening products. This partnership will leverage Thermo Fisher's technology to enhance Mainz Biomed's mRNA-based screening tests. These tests aim to improve early detection of colorectal cancer and precancerous lesions, showcasing promising results in trials across the US and Europe.
This collaboration will focus on developing proprietary assays at Mainz Biomed’s labs in Germany. Guido Baechler, CEO of Mainz Biomed, highlighted the potential for a home collection screening tool, emphasizing Thermo Fisher's contribution to accelerating innovation in cancer detection.
Peter Jacobs from Thermo Fisher expressed excitement about the partnership, anticipating rapid progress in bringing new assays to the global market. This alliance aims to deliver innovative solutions for colorectal cancer screening, furthering Mainz Biomed's product development capabilities.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Mainz BioMed N.V.